C
Christopher Sayed
Researcher at University of North Carolina at Chapel Hill
Publications - 72
Citations - 918
Christopher Sayed is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Hidradenitis suppurativa & Medicine. The author has an hindex of 9, co-authored 44 publications receiving 373 citations. Previous affiliations of Christopher Sayed include Central University of the Caribbean.
Papers
More filters
Journal ArticleDOI
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.
Ali Alikhan,Christopher Sayed,Afsaneh Alavi,Raed Alhusayen,Alain Brassard,Craig N. Burkhart,Karen Crowell,Daniel B. Eisen,Alice B. Gottlieb,Iltefat H. Hamzavi,Paul G. Hazen,Tara Jaleel,Alexa B. Kimball,Joslyn S. Kirby,Michelle A. Lowes,Robert G. Micheletti,Angela Miller,Haley B. Naik,Dennis P. Orgill,Yves Poulin +19 more
TL;DR: Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options.
Journal ArticleDOI
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management
Ali Alikhan,Christopher Sayed,Afsaneh Alavi,Raed Alhusayen,Alain Brassard,Craig N. Burkhart,Karen Crowell,Daniel B. Eisen,Alice B. Gottlieb,Iltefat H. Hamzavi,Paul G. Hazen,Tara Jaleel,Alexa B. Kimball,Joslyn S. Kirby,Michelle A. Lowes,Robert G. Micheletti,Angela Miller,Haley B. Naik,Dennis P. Orgill,Yves Poulin +19 more
TL;DR: An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and a therapeutic algorithm informed by the evidence available at the time of the review is provided.
Journal ArticleDOI
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project
Amit Garg,Erica Neuren,Denny Cha,Joslyn S. Kirby,John R. Ingram,Gregor B.E. Jemec,Solveig Esmann,L. Thorlacius,B. Villumsen,Véronique Del Marmol,Aude Nassif,Maïa Delage,Thrasyvoulos Tzellos,Dagfinn Moseng,Øystein Grimstad,Haley B. Naik,Robert G. Micheletti,S. Guilbault,Angie Parks Miller,Iltefat H. Hamzavi,Hessel H. van der Zee,Errol P. Prens,Naomi Kappe,Christine B. Ardon,Brian Kirby,R. Hughes,Christos C. Zouboulis,Georgios Nikolakis,Falk G. Bechara,Lukasz Matusiak,Jacek C Szepietowski,Amelia Głowaczewska,Saxon D Smith,Noah Goldfarb,Steven Daveluy,Christina Avgoustou,Evangelos J. Giamarellos-Bourboulis,Steven R. Cohen,Yssra Soliman,Elena Gonzalez Brant,Oleg E. Akilov,Christopher Sayed,Jerry Tan,Afsaneh Alavi,Michelle A. Lowes,José C. Pascual,Hassan Riad,Shani Fisher,Arnon D. Cohen,So Yeon Paek,Barry I. Resnik,Qiang Ju,Lanqi Wang,Andrew Strunk +53 more
TL;DR: HS patients have identified several critical unmet needs that will require stakeholder collaboration to meaningfully address in multidisciplinary care, treatment, research, advocacy, and philanthropy.
Journal ArticleDOI
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations
Amit Garg,Neeta Malviya,Andrew Strunk,Shari Wright,Afsaneh Alavi,Raed Alhusayen,Ali Alikhan,Steven Daveluy,Isabelle Delorme,Noah Goldfarb,Wayne Gulliver,Iltefat H. Hamzavi,Tarannum Jaleel,Alexa B. Kimball,Joslyn S. Kirby,Mark G. Kirchhof,Janice Lester,Hadar Lev-Tov,Michelle A. Lowes,Robert G. Micheletti,Lauren A.V. Orenstein,Vincent Piguet,Christopher Sayed,Jerry Tan,Haley B. Naik +24 more
TL;DR: In this paper, the authors provide evidence-based screening recommendations for comorbidities linked to Hidradenitis suppurativa (HS) in patients relative to the general population.
Journal ArticleDOI
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Sophie Glatt,Gregor B.E. Jemec,Seth B Forman,Christopher Sayed,George Schmieder,Jamie Weisman,R. Rolleri,Seth D Seegobin,Dominique Baeten,Lucian Ionescu,Christos C. Zouboulis,Stevan Shaw +11 more
TL;DR: Initial clinical efficacy and safety data suggest that dual inhibition of interleukin 17A and 17F by bimekizumab may be a viable treatment approach for HS, with the potential to achieve deep responses in clinical outcome measures, and support further evaluation.